Cellectis shares are trading higher after the company announced that the FDA granted Regenerative Medicine Advanced Therapy designation to lasmecabtagene timgedleucel

Benzinga Newsdesk www.benzinga.com Positive 95.0%

Neg 0% Neu 0% Pos 95%

Comments

No comments yet. Be the first!